Frédérique Dol-Gleizes

Author

Sanofi (France)

Also Known As

Frederique Dol-Gleizes, Frédérique Dol-Gleizes, Frédérique Dol-Gleizes

Publications

361

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Inserm

About

Frédérique Dol-Gleizes is an author at Sanofi (France) specializing in medicine, physiology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	214
2	Pharmacology	3	3	177
3	Health Sciences	1	1	11
4	Natural Sciences	1	1	146
5	Diabetes	1	1	11

Frédérique Dol-Gleizes

Publications

359

Citations

H-Index

Page 1

	Year	Citations
Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties Françoise Bono, Frederik De Smet, Corentin Herbert, Cancer Cell AngiogenesisMedicineNatural SciencesSmall MoleculesCancer Growth	2013	146
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice Frédérique Dol-Gleizes, Réjane Paumelle, Virgile Visentin, Arteriosclerosis Thrombosis and Vascular Biology	2008	123
P2Y4 nucleotide receptor: a novel actor in post-natal cardiac development Michael Horckmans, Bernard Robaye, Elvira Léon-Gómez, Angiogenesis Cardiac MuscleCardiomyopathyMolecular PhysiologyDevelopmental BiologyP2y4 Nucleotide Receptor	2012	37
Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel Frédérique Dol-Gleizes, Anne-Marie Marés, Pierre Savi, European Journal of Pharmacology Rat Thoracic AortaCardiovascular DiseaseMedicineVascular PharmacologyPhysiology	1999	20
A New Synthetic FGF Receptor Antagonist Inhibits Arteriosclerosis in a Mouse Vein Graft Model and Atherosclerosis in Apolipoprotein E-Deficient Mice Frédérique Dol-Gleizes, Nathalie Delesque-Touchard, Anne-Marie Marés, PLoS ONE	2013	11
Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice Paul Schaeffer, A. Bernat, M. Arnone, European Journal of Pharmacology InflammationMolecular PharmacologyMetabolic SyndromeAnti-inflammatoryAdrenal Gland	2005	11
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy Michaël R. Paillasse, Michaël Esquerré, Florie A. Bertrand, Cancer Research Communications	2022	11

Page 1